Congresses and Meetings

The fact that Claret Medical’s Cerebral Protection system is not yet approved for use in U.S. TAVR procedures looks like an anachronism following study results that point to a high risk procedure and a solution that works.

A newly presented study shows so-called Autonomic Regulation Therapy (ART) in patients with moderate to severe chronic heart failure and impaired heart function improves the heart’s ability to pump blood, and reduces HF-associated symptoms.

Newly presented data says that using FFR measurement technology changed the course of treatment for more than one fifth of patients suffering non-ST segment elevation myocardial infarction (NSTEMI) heart attacks.

Codman Neuro has chosen the SNIS meeting at which to launch the ENVOY® DA XB Distal Access Guiding Catheter and the 7F ENVOY® Guiding Catheter for neurovascular procedures.

Sports Med device maker Mitek’s gone all biotherapy on us with its newly announced launch of MONOVISC® High Molecular Weight Hyaluronan and the PEAK™ Platelet Rich Plasma (PRP) System

Covidien has announced the launch of its new Pipeline Flex Neuro-Embolization device which is a minimally-invasive flow diversion device for unruptured brain aneurysms, now claiming more accurate, controlled placement.

New data further demonstrate the acute effects of EndoBarrier® Therapy on glycemic control, its ability to reduce reliance on diabetes medications and potential mechanism of action.

Cardiovascular Systems, Inc. points us at one-year data and a new economic analysis from its ORBIT II coronary study in a late-breaker session at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 conference last week.

Annual EFORT exhibition in London to headline ExactechGPS® Guided Personalized Surgery from Exactech.

Results relating to the ConforMIS, Inc. iTotal® patient-specific total knee replacement have been presented at the British Association for Surgery of the Knee (BASK) meeting in Norwich, UK.

Results showing that use of the BioMimics 3D ™ vascular stent offer improved maintenance of patency over two years compared with traditional straight stent, have been presented at last week’s NCVH conference.

New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.

OrbusNeich’s novel COMBO™ Dual Therapy Stent has been shown in a three year study to actively promote rapid endothelialization and deliver long-term, true vessel healing with no thrombotic events reported.

Direct Flow Medical tells us about positive 12 month outcomes from the DISCOVER CE Mark Trial. Results were featured at this week’s EuroPCR in an oral presentation by principal investigator Joaquim Schofer, MD, from the Medical Care Center, Hamburg, Germany.

STENTYS, with its clever world-first (and indeed only) Self-Apposing® Stent to treat acute myocardial infarction (AMI), has seen final results from the APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) presented during the Hotline session at the EuroPCR conference in Paris.

Interventional Pulmonology company Pulmonx has announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its Chartis Pulmonary Assessment System and Zephyr® Valve have been presented at the American Thoracic Society International Conference.